Sascha Dublin, MD, PhD

Sascha Dublin

“My work helps people know what medications are safe, especially for vulnerable populations like pregnant women and older adults.”

Sascha Dublin, MD, PhD

Senior Investigator, Kaiser Permanente Washington Health Research Institute
Physician, Washington Permanente Medical Group, Internal Medicine
Affiliate Associate Professor, Kaiser Permanente Bernard J. Tyson School of Medicine

Sascha.Dublin@kp.org
206-287-2870

Biography

Sascha Dublin, MD, PhD, is a general internist and epidemiologist who studies the health effects of prescription medications and other interventions using real-world health care data. Through her work, she aims to provide better information about the risks and benefits of different treatments so patients and doctors can make well-informed decisions.

Much of Dr. Dublin’s research focuses on the outcomes of medication use or other interventions during pregnancy. These studies take advantage of the rich clinical data available through electronic health records (EHRs). Some of her current work in this area includes:

  • comparing different treatments for hypertension in pregnancy, looking at both the safety and effectiveness of various medications;
  • working with the U.S. Food and Drug Administration (FDA) to study whether prescription opioid use in pregnancy increases the risk of birth defects; and
  • studying the impact of treating mild to moderate hypertension during pregnancy through an R01 grant from the National Institute of Child Health and Human Development.

Dr. Dublin recently led an impactful study with Kaiser Permanente Washington Health Research Institute colleagues exploring different methods to screen for diabetes in pregnancy. This work examined how outcomes changed for mothers and babies after Kaiser Permanente Washington made a big shift in their approach to gestational diabetes screening. This project found that a new, more intensive approach to screening did not improve health outcomes, and may have even worsened some. As a result, Kaiser Permanente Washington changed back to the previous, more widely used screening approach.

Beyond pregnancy, Dr. Dublin’s work includes studies of medication use and dementia risk in older adults. For example, her team found that heavy use of some commonly used medications including antihistamines increases dementia risk.  They also found that one widely used medication class, proton pump inhibitors, does not increase the risk of dementia—in contrast to some earlier reports—or fractures. 

Dr. Dublin has a strong interest in epidemiologic methods, particularly finding ways to better measure important variables. She has led methods workgroups for the FDA’s Sentinel Initiative and has experience using natural language processing and collecting data from patients through mobile phone apps. Dr. Dublin also has interest and expertise in improving the rigor and validity of observational studies by improving how they account for patients’ other illnesses and overall health status.

Dr. Dublin previously held a Paul B. Beeson Career Development Award (K23) from the National Institute on Aging. She sees patients one day a week in primary care at Kaiser Permanente Washington.

 ​​

Research interests and experience 

  • Aging & Geriatrics

    Medications and risk of cognitive decline; use of preventive medications; age-related disease and disability
  • Cardiovascular Health

    Epidemiology
  • Medication Use & Patient Safety

    Medication safety in vulnerable populations including older adults and pregnant women
  • Women’s Health

    Safety and effectiveness of interventions during pregnancy; medication use and safety during pregnancy
  • Child & Adolescent Health

    Impact of in utero medication exposure on the fetus or infant

Vaccines & Infectious Diseases

 

Recent publications

Li Q, Andrade SE, Cooper WO, Davis RL, Dublin S, Hammad TA, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Dashevsky I, Haffenreffer K, Johnson KE, Toh S. Validation of an algorithm to estimate gestational age in electronic health plan databases. Pharmacoepidemiol Drug Saf. 2013 May;22(5):524-32. doi: 10.1002/pds.3407. Epub 2013 Jan 21. PubMed

Avery TR, Kulldorff M, Vilk Y, Lingling L, Cheetham TC, Dublin S, Davis RL, Liu L, Herrinton L, Brown JS. Near real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual. Pharmacoepidemiol Drug Saf. 2013 May;22(5):488-95. doi: 10.1002/pds.3412. Epub 2013 Feb 12. PubMed

Toh S, Li Q, Cheetham TC, Cooper WO, Davis RL, Dublin S, Hammad TA, Li DK, Pawloski PA, Pinheiro SP, Raebel MA, Scott PE, Smith DH, Bobo WV, Lawrence JM, Dashevsky I, Haffenreffer K, Avalos LA, Andrade SE. Prevalence and trends in the use of antipsychotic medications during pregnancy in the U.S., 2001-2007: a population-based study of 585,615 deliveries. Arch Womens Ment Health. 2013 Apr;16(2):149-57. doi: 10.1007/s00737-013-0330-6. Epub 2013 Feb 7. PubMed

Thacker EL, McKnight B, Psaty BM, Longstreth WT Jr, Dublin S, Jensen PN, Newton KM, Smith NL, Siscovick DS, Heckbert SR. Association of body mass index, diabetes, hypertension, and blood pressure levels with risk of permanent atrial fibrillation.  J Gen Intern Med. 2013 Feb;28(2):247-53. doi: 10.1007/s11606-012-2220-4. Epub 2012 Sep 13. PubMed

 

Research

COVID-and-estrogen_op3_1col.jpg

COVID risks not meaningfully greater with estrogen-containing medications

Oral contraceptives, hormone therapy not linked to more severe COVID outcomes.

Research

Multiracial women enjoying working out together outside

Personalized coaching shows promise for delaying memory loss

Trial is the first to test an individualized approach to improve dementia risk factors.

Research

Female doctor and senior female patient sitting around desk

Dementia risk screening tool shows promise

In a new study, a tool to help discover undiagnosed dementia performed well in 2 separate health systems.

Research

Hypertension-in-pregnancy_1col.jpg

New findings on treating hypertension in pregnancy

A study led by Dr. Sascha Dublin finds similar outcomes for 3 hypertension medications, filling an evidence gap.